blood
coagul
inflamm
univers
respons
infect
crosstalk
inflamm
coagul
either
amplifi
dampen
respons
loss
appropri
interact
system
probabl
contribut
morbid
mortal
infecti
diseas
instanc
inflammatori
cytokin
leukocyt
elastas
downregul
natur
anticoagul
protein
help
maintain
endothelialcel
integr
control
clot
inhibit
vasoact
peptid
dampen
leukocyt
infiltr
vessel
wall
review
summar
current
understand
mechan
involv
crosstalk
two
import
system
infecti
agent
regardless
natur
initi
innat
immun
respons
turn
trigger
blood
coagul
instanc
viral
infect
sever
acut
respiratori
syndrom
sar
progress
sever
sepsi
marker
blood
coagul
increas
markedli
blood
coagul
compon
simpli
bystand
either
amplifi
inhibit
inflammatori
respons
blood
clot
initi
inflammatori
cytokin
endotoxin
induc
de
novo
synthesi
tissu
factor
leukocyt
exposur
tissu
factor
blood
trigger
coagul
cascad
complement
activ
lead
format
plasma
membran
surfac
enrich
neg
charg
phospholipid
amplifi
coagul
reaction
oppos
coagul
cascad
natur
anticoagul
pathway
pathway
limit
coagul
respons
also
dampen
inflammatori
respons
minim
leukocyt
chemotaxi
endothelialcel
interact
suppress
apoptosi
reduc
cytokin
express
howev
acut
inflammatori
respons
lead
suppress
natur
anticoagul
pathway
consumpt
proteolyt
inactiv
downregul
protein
express
loss
coordin
control
coagul
inflamm
pathway
due
impair
function
natur
anticoagul
system
probabl
contribut
organ
failur
sever
sepsi
blood
clot
process
extrem
complex
biochem
detail
review
ref
briefli
blood
coagul
initi
tissu
factor
come
contact
blood
figur
normal
circumst
littl
tissu
factor
intravascular
compart
tissu
factor
found
constitut
express
extravascular
cell
surround
vessel
provid
mechan
rapid
seal
breach
vessel
integr
recent
studi
indic
circul
form
tissu
factor
probabl
local
leukocytederiv
microparticl
microparticlebound
tissu
factor
might
concentr
pselectin
activ
platelet
form
thrombi
interact
ligand
psgl
pselectin
glycoprotein
ligand
activ
leukocyt
inflammatori
stimuli
increas
respons
stimul
tissu
factor
synthesi
promot
microparticl
format
microparticl
express
high
level
neg
charg
phospholipid
surfac
thu
promot
tissu
factorfactor
viiamedi
factor
x
ix
activ
enabl
propag
coagul
factor
xafactor
va
activ
prothrombin
factor
ixafactor
viiia
activ
factor
x
potent
platelet
agonist
thrombin
combin
collagen
complement
augment
avail
neg
charg
phospholipid
membran
surfac
cell
particularli
platelet
thu
enabl
amplif
coagul
system
initi
coagul
pathway
potenti
gener
time
thrombin
requir
form
rapid
firm
clot
condit
prevent
natur
anticoagul
mechan
major
inhibitori
mechan
involv
protein
c
anticoagul
pathway
antithrombinheparin
tissu
factor
pathway
inhibitor
tfpi
protein
c
pathway
trigger
thrombin
bind
thrombomodulin
endothelialcel
surfac
complex
concert
protein
c
bound
endothelialcel
protein
c
receptor
epcr
gener
activ
protein
c
activ
protein
c
dissoci
epcr
bind
protein
membran
surfac
activ
protein
cprotein
complex
inactiv
factor
va
viiia
without
cofactor
factor
xa
factor
ixa
much
less
capac
activ
downstream
zymogen
practic
mean
inactiv
cofactor
shut
coagul
system
complet
addit
rel
thrombin
solut
thrombin
bound
thrombomodulin
inhibit
much
rapidli
antithrombin
protein
c
inhibitor
antithrombinheparin
mechan
neutral
factor
xa
thrombin
factor
ixa
also
inactiv
factor
viia
factor
viia
bound
tissu
factor
antithrombin
inhibit
factor
viiatissu
factor
complex
factor
ixa
factor
xa
thrombin
thought
acceler
vascular
heparinlik
proteoglycan
tfpi
inactiv
factor
viia
bound
tissu
factor
use
uniqu
mechan
inhibitor
two
function
inhibitori
kunitz
domain
second
domain
bind
inhibit
factor
xa
result
abil
bind
neg
charg
membran
concentr
tfpifactor
xa
complex
membran
surfac
time
first
kunitz
domain
inhibitor
revers
neutral
factor
viia
physiolog
signific
pathway
demonstr
gene
experi
mice
result
embryon
neonat
lethal
singl
pathway
disrupt
human
complet
defici
protein
c
lead
neonat
microvascular
thrombosi
purpura
fulminan
subsequ
death
unless
treat
complet
defici
antithrombin
tfpi
human
describ
inflamm
multipl
effect
coagul
system
figur
antithrombin
consum
andor
inactiv
sepsi
acut
inflammatori
injuri
antithrombin
inhibitori
activ
decreas
markedli
sever
sepsi
often
normal
level
rate
inhibit
target
proteas
strongli
depend
antithrombin
concentr
decreas
inhibitor
concentr
would
contribut
increas
stabil
coagul
enzym
henc
favor
intravascular
coagul
evid
vascular
heparinlik
molecul
reduc
inflammatori
cytokin
neutrophil
activ
product
clinic
sever
sepsi
heparinlik
molecul
downregul
degrad
diminish
natur
anticoagul
potenti
especi
antithrombin
level
reduc
consumpt
protein
c
pathway
appear
especi
sensit
downregul
inflammatori
respons
tumor
necrosi
factora
tnfa
endotoxin
downregul
thrombomodulin
epcr
inhibit
gene
transcript
reduc
abil
gener
activ
protein
c
neutrophil
elastas
cleav
thrombomodulin
endothelialcel
surfac
gener
much
less
activ
form
thrombomodulin
septic
patient
epcr
thrombomodulin
sever
downregul
demonstr
immunohistochem
analysi
abil
patient
gener
activ
protein
c
addit
protein
c
level
decreas
dramat
patient
sever
sepsi
probabl
due
combin
consumpt
liver
main
site
protein
c
synthesi
dysfunct
degre
protein
c
reduct
correl
neg
prognosi
septic
patient
tight
control
thrombin
coagul
enzym
lost
particip
promot
inflammatori
respons
figur
enhanc
inflammatori
respons
enhanc
cellassoci
coagul
activ
describ
earlier
therefor
anticoagul
dampen
cellular
inflammatori
respons
also
dampen
coagul
respons
antithrombinheparin
pathway
modul
inflammatori
respons
inhibit
coagul
enzymemedi
cell
signal
proteas
activ
receptor
also
modul
cellular
respons
antithrombin
downregul
express
leukocyt
factor
x
bind
receptor
augment
factor
x
activ
downregul
cellular
factor
x
receptor
decreas
leukocyt
adhes
coagul
addit
antithrombin
endotheli
cell
cultur
increas
prostacyclin
format
decreas
nfkb
signal
modul
cellular
respons
endotoxin
antithrombin
appear
decreas
tissu
factor
express
monocyt
endothelium
antithrombin
bind
syndecan
proteoglycan
neutrophil
inhibit
chemokineinduc
neutrophil
migrat
interestingli
heparin
block
effect
addit
administr
high
level
antithrombin
septic
experiment
anim
anim
undergo
ischemia
reperfus
injuri
revers
leukocyt
recruit
figur
protein
c
anticoagul
pathway
sever
compon
reduc
inflammatori
respons
thrombomodulin
increas
protein
c
activ
also
prevent
thrombin
activ
proteaseactiv
receptor
par
accomplish
least
part
site
thrombin
anion
bind
exosit
respons
bind
thrombomodulin
overlap
figur
addit
thrombin
bound
thrombomodulin
gain
abil
activ
plasma
procarboxypeptidas
r
also
known
thrombin
activat
fibrinolysi
inhibitor
tafi
recent
studi
shown
carboxypeptidas
potent
inhibitor
complement
anaphylatoxin
bradykinin
inhibit
vasoact
substanc
gener
carboxypeptidas
especi
microcircul
probabl
help
prevent
sever
drop
blood
pressur
microvascular
injuri
subsequ
edema
anim
sever
acut
inflammatori
injuri
addit
function
recent
studi
shown
thrombomodulin
direct
antiinflammatori
activ
endothelium
thrombomodulin
multidomain
molecul
ntermin
lectin
domain
delet
protein
c
carboxypeptidas
r
activ
proceed
normal
howev
mutant
use
replac
normal
thrombomodulin
gene
mice
mice
recruit
leukocyt
much
avidli
wildtyp
mice
respons
inflammatori
stimuli
infus
isol
lectin
domain
revers
respons
cell
cultur
studi
demonstr
domain
dampen
mitogen
activ
kinas
nfkb
respons
endothelium
activ
protein
c
dampen
nfkb
signal
monocyt
also
decreas
inflammatori
mediatoriniti
gener
tissu
factor
leukocyt
cell
line
epcr
depend
fashion
addit
activ
protein
c
inhibit
tight
neutrophil
adhes
endothelium
activ
protein
c
also
decreas
endothelialcel
apoptosi
function
depend
epcr
appar
involv
activ
mous
model
stroke
activ
protein
c
minim
damag
least
part
inhibit
apoptosi
downregul
inhibit
express
also
depend
epcr
activ
gener
antiinflammatori
activ
remain
area
activ
investig
recent
determin
epcr
structur
suggest
addit
potenti
role
protein
c
pathway
regul
immun
respons
epcr
share
consider
sequenc
ident
mhc
famili
molecul
crystal
structur
epcr
reveal
like
famili
epcr
tightli
bound
lipid
case
phospholipid
locat
region
virtual
ident
antigenpres
groov
famili
figur
protein
glycolipid
bind
grove
major
role
immun
respons
bacteri
infect
addit
defici
mice
lead
autoimmun
diseas
structur
similar
probabl
yet
unproven
epcr
might
role
similar
molecul
regul
inflamm
autoantibodi
epcr
correl
autoimmun
fetal
loss
recent
demonstr
consist
involv
immun
regul
platelet
also
involv
link
inflamm
coagul
inflammatori
mediat
increas
platelet
product
platelet
gener
thrombogen
demonstr
increas
sensit
platelet
agonist
thrombin
platelet
contain
high
concentr
proinflammatori
mediat
ligand
platelet
activ
ligand
releas
protein
induc
tissu
factor
synthesi
increas
inflammatori
cytokin
clot
process
involv
molecul
selectin
origin
thought
involv
primarili
inflamm
box
natur
anticoagul
protein
exhibit
spectrum
antiinflammatori
activ
includ
inhibit
nfkb
signal
inhibit
complement
bradykinin
prevent
apoptosi
sever
acut
inflammatori
challeng
downregul
natur
anticoagul
therebi
diminish
abil
dampen
coagul
inflammatori
respons
happen
progress
cycl
evolv
coagul
increas
inflammatori
respons
therebi
increas
coagul
respons
sever
vascular
organ
injuri
occur
modul
complex
seri
interact
event
promis
offer
attract
method
interven
clinic
diseas
involv
acut
inflammatori
thrombin
coagul
enzym
react
preferenti
bound
case
requir
bind
glycosaminoglycan
syndecan
bind
inhibitor
major
conform
chang
occur
lead
releas
complex
absenc
bind
glycosaminoglycan
lead
cell
signal
increas
prostacyclin
pgi
format
decreas
nfkb
activ
review
trend
immunolog
vol
octob
challeng
sever
sepsi
recent
success
demonstr
recombin
activ
protein
c
reduc
caus
mortal
patient
sever
sepsi
provid
support
propos
interest
antithrombin
tfpi
fail
larg
random
clinic
trial
despit
similar
activ
protein
c
proven
efficaci
nonhuman
primat
model
sever
sepsi
sever
possibl
could
explain
failur
natur
anticoagul
tfpi
antithrombin
trial
first
clinic
situat
bleed
complic
limit
dosag
greater
extent
anim
studi
instanc
anticoagul
dose
baboon
sepsi
model
much
higher
human
trial
therefor
dose
anticoagul
might
adequ
antithrombin
trial
heparin
use
mani
patient
note
earlier
heparin
block
sever
cellular
effect
antithrombin
although
overal
effect
surviv
antithromin
patient
heparin
alon
antithrombin
alon
tend
better
surviv
rate
patient
receiv
altern
trial
result
differ
lie
differ
function
among
natur
anticoagul
antithrombin
activ
protein
c
share
sever
antiinflammatori
function
vitro
anim
model
studi
explor
differ
natur
anticoagul
respect
cellular
respons
particular
vascular
bed
impact
ongo
inflammatori
challeng
place
time
inhibitor
administr
furthermor
patient
popul
mani
comorbid
might
decreas
efficaci
one
inhibitor
select
comorbid
atherosclerosi
diabet
hypertens
exacerb
innat
inflammatori
respons
varieti
mechan
includ
downregul
natur
anticoagul
figur
epcr
molecul
portion
pc
gla
domain
lipid
molecul
epcr
yellow
ribbon
two
ahelic
eightstrand
bsheet
creat
groov
fill
phospholipid
space
fill
blue
ball
center
bind
ca
ion
magenta
sphere
pc
gla
domain
green
ribbon
expos
ntermin
omega
loop
absenc
epcr
interact
phospholipid
surfac
membran
appear
direct
interact
pc
gla
domain
lipid
molecul
locat
groov
epcr
model
complex
consist
residu
rsepcr
first
residu
pc
gla
domain
abbrevi
epcr
endothelialcel
protein
c
receptor
pc
protein
c
exact
signal
mechan
respons
protect
effect
natur
anticoagul
need
character
fulli
preclin
level
differ
protect
effect
natur
anticoagul
need
explor
fulli
particularli
situat
diseas
alreadi
progress
would
almost
alway
case
patient
futur
research
also
need
address
impact
common
diseas
process
diabet
innat
immun
respons
abil
natur
anticoagul
pathway
modul
innat
immun
respons
combin
microarray
proteom
approach
might
aid
studi
addit
although
understand
regul
blood
coagul
system
artifici
membran
surfac
rel
sophist
cellular
control
coagul
still
emerg
area
instanc
activ
protein
c
potent
anticoagul
involv
liposom
contrast
rel
poor
anticoagul
platelet
surfac
model
system
blood
coagul
platelet
present
endothelium
appear
activ
protein
c
anticoagul
function
occur
endotheli
cell
rather
platelet
surfac
natur
membran
surfac
respons
differ
remain
elucid
